

Clinical Quality Measures

2023 measurement year

Measure		Rating	Rate
Adolescent Depression	PHQ-9 Utilization*	-	-
	Follow-up at Six Months	Expected	54.10%
	Response at Six Months	Expected	10.80%
	Remission at Six Months	Expected	2.70%
	Follow-up at 12 Months	Expected	40.50%
	Response at 12 Months	Expected	18.90%
	Remission at 12 Months	Expected	10.80%
Adult Depression	PHQ-9 Utilization*	Above	95.20%
	Follow-up at Six Months	Expected	49.20%
	Response at Six Months	Expected	18.60%
	Remission at Six Months	Expected	11.50%
	Follow-up at 12 Months	Above Expected	60.00%
	Response at 12 Months	Above Expected	25.30%
	Remission at 12 Months	Above Expected	17.00%
Adolescent Mental Health and/or Depression Screening*		Above	99.50%
Colorectal Cancer Screening		Above Expected	75.00%
Optimal Asthma Control - Adults		Above Expected	65.50%
Optimal Asthma Control - Children		Above Expected	69.60%
Optimal Diabetes Care		Expected	45.50%
HbA1c Control		Expected	72.20%
BP Control		Above Expected	86.80%
Daily Aspirin Use		Expected	98.60%
Statin Use		Above Expected	92.90%
Tobacco-Free		Below Expected	75.80%
Optimal Vascular Care		Expected	55.90%
BP Control		Above Expected	87.00%
Daily Aspirin Use		Expected	89.00%
Statin Use		Above Expected	95.10%
Tobacco-Free		Below Expected	74.80%

- Medical group not assigned to measure, did not have results, or did not meet reporting threshold

*Measure not risk adjusted

Healthcare Effectiveness Data and Information Set (HEDIS) Measures

2023 measurement year

Measure	Rating	Rate
Avoidance of Antibiotic Treatment in Acute Bronchitis/Bronchiolitis	Average	56.00%
Breast Cancer Screening	Below	65.20%
Cervical Cancer Screening	Above	84.00%
Childhood Immunization Status (Combo 10)	Below	36.50%
Chlamydia Screening in Women	Average	51.80%
Controlling High Blood Pressure	Above	81.10%
Diabetes Eye Exam	Average	65.00%
Immunizations for Adolescents (Combo 2)	Below	17.30%
Follow-up Care for Children Prescribed ADHD Medication	Average	39.60%
Osteoporosis Management in Women Who Had a Fracture	Average	36.60%
Use of Spirometry Testing in the Assessment and Diagnosis of COPD	Above	51.80%

- Medical group not assigned to measure, did not have results, or did not meet reporting threshold

Ratings

Above: Medical group's actual rate is significantly above its expected rate (for risk adjusted measures) or the statewide/medical group rate (for unadjusted/HEDIS measures).

Average: Medical group's actual rate is not statistically different than its expected rate (for risk adjusted measures) or the statewide/medical group rate (for unadjusted/HEDIS measures).

Below: Medical group's actual rate is significantly below its expected rate (for risk adjusted measures) or the statewide/medical group rate (for unadjusted/HEDIS measures).

Total Cost of Care

2023 measurement year

Population	Monthly Average Cost	Rating	Higher/Lower than Average
Overall	\$761	Higher than average	7.50%
Adults	\$899	Higher than average	8.20%
Pediatric	\$341	Average	0.00%